Browsing by Author "Wimalasingham, AG"
Now showing items 1-3 of 3
-
Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)-deficient non-squamous non-small cell lung cancer.
Wimalasingham, AG; Phillips, MM; Lim, L; Rashid, S; Hall, PE; Khadeir, R; Steele, JPC; Conibear, J; Feng, X; Ellis, S (2019-05-20) -
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer
Szlosarek, PW; Wimalasingham, AG; Phillips, MM; Hall, PE; Chan, PY; Conibear, J; Lim, L; Rashid, S; Steele, J; Wells, P (Wiley, 2021-08-12)Introduction We evaluated the arginine-depleting enzyme pegargiminase (ADI-PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1-deficient non-squamous non-small cell lung cancer (NSCLC) via a phase 1 ... -
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer
Davies, CR; Guo, T; Burke, E; Stankiewicz, E; Xu, L; Mao, X; Scandura, G; Rajan, P; Tipples, K; Alifrangis, C (Frontiers Media, 2023-01-16)Background: Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired ...